v3.26.1
Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Significant Revenue and Expense Categories
The table below summarizes the significant revenue and expense categories regularly reviewed by the CEO for the three and six months ended June 30, 2026 and 2025:
For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
Revenue:
Product revenue, net$5,093 $4,534 $9,383 $7,956 
License and collaboration revenue769 8,168 1,502 8,185 
Total revenue5,862 12,702 10,885 16,141 
Less:
Cost of product revenue
435 340 979 763 
Cost of license and collaboration revenue
443 154 788 168 
Selling, general and administrative:
Commercial (including payroll)5,676 4,346 11,373 8,628 
General and administrative (including payroll)3,874 3,918 7,573 7,699 
Stock-based compensation799 588 1,392 1,373 
Total selling, general and administrative expense10,349 8,852 20,338 17,700 
Research and development:
YCANTH (VP-102)808 340 1,086 711 
VP-31568 33 201 194 
Common warts3,377 (93)5,008 (66)
Stock-based compensation396 300 672 541 
Other unallocated expenses1,385 1,266 2,927 2,750 
Total research and development expense6,034 1,846 9,894 4,130 
Legal settlement, net of insurance recovery
1,698 — 1,698 — 
Other:
Other expense (a)56 1,306 23 2,918 
Net (loss) income$(13,153)$204 $(22,835)$(9,538)
(a)Other expense includes interest income, interest expense, change in fair value of derivative liability and other expenses.
Schedule of Basic and Diluted Earnings Per Share
For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
Net (loss) income attributable to common stockholders - basic$(13,153)$204 $(22,835)$(9,538)
Weighted average common shares outstanding - basic21,305,0259,488,05521,305,0259,485,907
Net (loss) income per share - basic$(0.62)$0.02 $(1.07)$(1.01)
Net (loss) income attributable to common stockholders - diluted$(13,153)$204 $(22,835)$(9,538)
Weighted average common shares outstanding - basic21,305,025 9,488,055 21,305,025 9,485,907 
Restricted stock units— 1,715 — — 
Stock options— 830 — — 
Weighted average common shares outstanding - diluted21,305,0259,490,60021,305,0259,485,907
Net (loss) income per share - diluted$(0.62)$0.02 $(1.07)$(1.01)
Schedule of Potential Shares Outstanding not Included in Computation of Diluted Net Loss Per Common Share
The table below provides potential shares outstanding that were not included in the computation of diluted net loss per common share, as the inclusion of these securities would have been anti-dilutive:
June 30,
20262025
Shares issuable upon exercise of stock options2,895,1271,066,643
Non-vested shares under restricted stock grants—25,000
Shares issuable upon exercise of warrants pursuant to debt financing51,85551,855
Shares issuable upon exercise of warrants pursuant to Torii amendment50,00050,000
Shares issuable upon exercise of Series A and B warrants pursuant to 2024 equity financing2,387,7034,775,406
Shares issuable upon exercise of Series C warrants pursuant to the Private Placement
2,951,241—
Total8,335,9265,968,904